COMMUNIQUÉS West-GlobeNewswire

Glucotrack Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
30/03/2026
Company prepares to file Investigational Device Exemption (IDE) for Novel CBGM Technology, targeting US Clinical Trial Launch in Second Half of 2026 US Patent and Trademark Office (USPTO) issued patents for Glucotrack’s [...]
Artelo Biosciences Announces Closing of $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
30/03/2026
SOLANA BEACH, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) today announced the closing of its previously announced private placement of 3,188,407 shares of common stock (or pre- [...]
ProHealth Longevity BPC‑157 Claims Evaluated: Most Effective BPC157 Peptide Brand on the Market (2026)
30/03/2026
A 2026 consumer information guide examining ProHealth BPC-157 oral peptide capsule details, arginate vs acetate formulation context, preclinical tissue repair research, regulatory status, third-party testing [...]
Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update
30/03/2026
REDWOOD CITY, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy [...]
Vireo Growth Inc. Announces Effectiveness of Management Services Agreement with PharmaCann Inc.
30/03/2026
Management Services Agreement went into effect on March 22, 2026, allowing Vireo to manage certain PharmaCann Colorado assets through closing, which is expected in Q2’26 MINNEAPOLIS, March 30, 2026 (GLOBE NEWSWIRE) -- [...]
Teladoc Health Appoints Susan Salka, Experienced Healthcare Executive, to Its Board of Directors
30/03/2026
NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced the appointment of Susan Salka to its board of directors, effective immediately. Ms. Salka is [...]
River Oaks Treatment Center Dedicates Its Primary Mental Health Program on World Bipolar Day
30/03/2026
RIVERVIEW, Fla., March 30, 2026 (GLOBE NEWSWIRE) -- Dozens of Riverview community members and mental health providers gathered at River Oaks Treatment Center to mark the ribbon-cutting and dedication of its primary [...]
Vicarious Surgical Completes Integrated Benchtop Testing of Full Surgical Instrument Suite for Ventral Hernia Repair
30/03/2026
WALTHAM, Mass., March 30, 2026 (GLOBE NEWSWIRE) -- Vicarious Surgical Inc. (OTCQB: RBOT), a next-generation robotics technology company seeking to transform minimally invasive surgery (the “Company”), today announced [...]
BIO GREEN MED SOLUTION REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
30/03/2026
KUALA LUMPUR, MALAYSIA, March 30, 2026 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. ("BGMS," the "Company" or “we,” formerly Cyclacel Pharmaceuticals, Inc.) (NASDAQ: BGMS), a diversified company engaged primarily in [...]
Inventiva publie ses résultats financiers annuels 2025 et fait le point sur son activité
30/03/2026
Chiffre d'affaires de 4,5 millions d'euros pour l’année 2025 Trésorerie et équivalents de trésorerie à 99,3 millions d’euros et 131,6 millions d'euros en dépôts à court terme 1 au 31 décembre 2025 Réalisation d'une [...]
Inventiva reports 2025 full year results and provides a business update
30/03/2026
Revenues of €4.5 million for the full year of 2025 Cash and cash equivalents at €99.3 million, and €131.6 million in short-term deposits 1 as at December 31, 2025 Completed a U.S. registered public offering for gross [...]
Palisade Bio Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn’s Disease
30/03/2026
PALI-2108 demonstrated favorable safety and tolerability with no serious adverse events after two weeks of treatment in a difficult-to-treat population Phase 1b data demonstrate endoscopic improvement, with a 47.5% [...]
Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs
30/03/2026
FDA assigned PDUFA target action date of September 27, 2026 BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision [...]
Interpace Biosciences Announces Fourth Quarter and Full Year 2025 Financial and Business Results
30/03/2026
Q4 and FY Revenue of $9.2 million and $38.7 million Q4 and FY Income from Continuing Operations of $22.8 million and $25.0 million (benefiting from a one-time, non-cash tax-related accounting adjustment) Q4 and FY [...]
Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results
30/03/2026
Progressing vision to expand the reach of targeted radiopharmaceuticals to large patient populations Anticipating multiple milestones in the next 12 months, including initiation of Phase 1b clinical trial of AKY-2519 in [...]
Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results
30/03/2026
Announced in June, positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in [...]
Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
30/03/2026
ARCHER II Topline Pivotal Phase 3 Data in Geographic Atrophy (GA) Expected Q4 2026; Vonaprument has Potential to Be the First Vision-Preserving Therapy for GA Tanruprubart MAA Filed in Europe with Potential to Be the [...]
RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update
30/03/2026
RenovoCath ® Generates $1.1 Million in 2025 Revenue in First Full Year of Commercialization Phase III TIGeR-PaC Trial on Track for Enrollment Completion by the Middle of 2026, and Final Data Anticipated in 2027 With $13 [...]
Beta Bionics to Announce First Quarter 2026 Financial Results on April 21, 2026
30/03/2026
IRVINE, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its first [...]

Pages